echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Neurology: Stroke symptoms as a surrogate measure of primary stroke prevention trials: CREST experience

    Neurology: Stroke symptoms as a surrogate measure of primary stroke prevention trials: CREST experience

    • Last Update: 2022-10-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Using alternative endpoints can reduce sample size
    while maintaining statistical power.
    A study published in Neurology identified stroke event symptoms as a surrogate endpoint for revascularization
    in asymptomatic patients in a multicenter randomized carotid artery post-hoc comparison of endartectomy versus stent placement trials (cREST).

    CREST assesses stroke symptoms
    using the Stroke-Free Status Questionnaire (QVSS) at baseline and follow-up.
    While the primary analysis at CREST defined "asymptomatic" as 180 days without stroke/transient ischemic attack (TIA), the population here is further limited
    by the need for stroke symptoms at baseline.
    The definition of stroke for event determination is the same as for the initial analysis; Incident stroke symptoms are defined as ≥ stroke symptoms
    occurring at follow-up.
    Three endpoints to assess differences in treatment for stenting (CAS) and endarterectomy (CEA): Diagnosed stroke, stroke symptoms, and Diagnosed stroke or stroke symptoms

    The low incidence of stroke events in asymptomatic patients challenges the assessment of differences in treatment between CAS and CEA
    Using event stroke symptoms as a surrogate result increased the number of events more than
    Analysis showed that previously unreported cerebrovascular risk factors differed significantly from
    those for cerebrovascular disease.
    It is suggested that broadening the endpoints of primary stroke prevention trials to include surrogate events such as stroke event symptoms could make the trial more feasible

    Source: Meschia JF, Brott TG, Voeks J, Howard VJ, Howard G.
    Stroke Symptoms As a Surrogate in Stroke Primary Prevention Trials: The CREST Experience [published online ahead of print, 2022 Aug 26].
    2022; 10.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.